BioAge Labs, Inc. announced full year 2025 financial results with $9.0 million collaboration revenue, $73.9 million R&D expenses, $27.8 million G&A expenses, and $80.6 million net loss. Highlights include positive interim Phase 1 data for BGE-102 demonstrating 86% median hsCRP reduction and plans for Phase 2a trials, plus $132.3 million follow-on offering extending cash runway through 2029.
Key takeaways
BGE-102 Phase 1 MAD cohort: 86% median hsCRP reduction, 58% IL-6 reduction, 30% fibrinogen reduction at 120 mg QD Day 14
Phase 2a proof-of-concept trial for BGE-102 in cardiovascular risk to initiate 1H 2026, data expected 2H 2026
BGE-102 expansion to diabetic macular edema: Phase 1b/2a trial to initiate mid-2026, data mid-2027
Completed upsized follow-on public offering of 6,782,050 shares at $19.50, gross proceeds $132.3 million in Feb 2026
$285.1 million in cash, cash equivalents, marketable securities as of Dec 31, 2025, sufficient through 2029
FY2025 collaboration revenue $9.0 million vs $0 in 2024, net loss $80.6 million vs $71.1 million